Aviragen Therapeutics
🇦🇺Australia
- Country
- 🇦🇺Australia
- Ownership
- Private
- Established
- 1984-01-01
- Employees
- 51
- Market Cap
- -
Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: vapendavir 132 mg capsuleDrug: vapendavir 264 mg tabletDrug: vapendavir 24 mg/mL oral suspension
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2018-11-26
- Lead Sponsor
- Aviragen Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT02877264
- Locations
- 🇺🇸
Aviragen Investigational Site, Saint Paul, Minnesota, United States
News
No news found